A 41-year-old man with generalised anxiety disorder has been taking sertraline 200mg daily for 12 weeks with minimal improvement. He has completed a full course of high-intensity CBT without significant benefit. His anxiety significantly impairs his ability to work and maintain relationships. On assessment, his GAD-7 score is 18. He has no history of substance misuse or bipolar disorder. What is the most appropriate next pharmacological management?
Q42
A 63-year-old woman with a 10-week history of severe depression presents with profound psychomotor retardation, complete loss of appetite with 8kg weight loss, and delusional beliefs that her internal organs are rotting. She refuses to eat or drink. Physical examination reveals marked dehydration. Blood tests show acute kidney injury. She has previously failed trials of sertraline and mirtazapine. What is the most appropriate next management step?
Q43
A 56-year-old woman with recurrent depressive disorder has been stable on fluoxetine 40mg daily for 18 months following her third depressive episode. She wishes to discontinue her antidepressant as she feels fully recovered and dislikes taking medication. Her previous episodes occurred 7 years ago and 4 years ago, both requiring 6-8 months of treatment. She has no current depressive symptoms and good social support. According to current NICE guidance, what is the most appropriate advice regarding discontinuation?
Q44
A 27-year-old man presents with panic disorder. He experiences unexpected panic attacks 4-5 times per week, characterized by palpitations, sweating, trembling, shortness of breath, and fear of dying. He has developed significant avoidance of situations where escape might be difficult. His GP has explained the diagnosis and offered treatment options. The patient is willing to try either medication or psychological therapy but wants to know which has the best evidence for long-term outcome. What does the evidence suggest about the comparative long-term effectiveness of CBT versus SSRIs for panic disorder?
Q45
A 48-year-old woman with treatment-resistant depression has failed adequate trials of sertraline, mirtazapine, and venlafaxine. She is currently taking venlafaxine 225mg daily. Her psychiatrist considers augmentation with lithium carbonate. Before initiating lithium, which combination of investigations must be performed as a baseline assessment?
Q46
A 33-year-old woman presents with recurrent panic attacks over the past 5 months. She describes sudden episodes of palpitations, sweating, trembling, and feeling like she cannot breathe, accompanied by intense fear of dying. Between attacks, she worries constantly about having another attack and has started avoiding shopping centres and public transport. She has no other psychiatric history. Cardiovascular examination and ECG are normal. She wishes to understand the psychological mechanisms underlying her condition. Which cognitive model best explains the maintenance of her panic disorder?
Q47
A 61-year-old woman with moderate depression has been taking citalopram 40mg daily for 4 weeks with good tolerability but minimal symptom improvement. Blood tests reveal a sodium level of 128 mmol/L (normal range 135-145 mmol/L). She is clinically euvolaemic with no signs of fluid overload or dehydration. Her thyroid function, glucose, and lipid profiles are normal. She takes no other regular medications. What is the most likely diagnosis?
Q48
A 44-year-old man with a 4-month history of panic disorder has been taking escitalopram 10mg daily for 6 weeks. He reports that the frequency of his panic attacks has reduced from daily to 2-3 times per week, but he still experiences significant anticipatory anxiety about having attacks. His GP considers increasing the dose. What is the maximum licensed daily dose of escitalopram for panic disorder?
Q49
A 38-year-old woman presents with a 6-month history of persistent, excessive worry about multiple everyday concerns including her children's safety, household finances, and her job performance. She finds the worry difficult to control and it occurs most days. She also reports feeling restless, experiencing muscle tension, having poor concentration, and feeling easily fatigued. She has no significant physical health problems. Her GAD-7 score is 16. She declined psychological therapy. What is the most appropriate first-line pharmacological treatment?
Q50
According to the ICD-10 diagnostic criteria for a depressive episode, what is the minimum duration of symptoms required to make this diagnosis?
Common Mental Disorders UK Medical PG Practice Questions and MCQs
Question 41: A 41-year-old man with generalised anxiety disorder has been taking sertraline 200mg daily for 12 weeks with minimal improvement. He has completed a full course of high-intensity CBT without significant benefit. His anxiety significantly impairs his ability to work and maintain relationships. On assessment, his GAD-7 score is 18. He has no history of substance misuse or bipolar disorder. What is the most appropriate next pharmacological management?
A. Switch to pregabalin
B. Add buspirone to current sertraline
C. Switch to duloxetine (Correct Answer)
D. Add diazepam 5mg three times daily for ongoing use
E. Augment with quetiapine
Explanation: ***Switch to duloxetine***
- According to **NICE guidelines**, if a first-line **SSRI** like sertraline is ineffective after an adequate trial, the next step is to offer an **alternative SSRI** or an **SNRI** such as **duloxetine** or venlafaxine.
- This patient has failed the maximum dose of sertraline and **high-intensity CBT**, making an **SNRI** the most logical and evidence-based pharmacological progression.
*Switch to pregabalin*
- While **pregabalin** is effective for GAD, it is generally considered a subsequent step after trials of an **alternative SSRI or SNRI** have failed.
- Clinical caution is required due to its status as a **controlled substance** and the potential for **dependence** and misuse.
*Add buspirone to current sertraline*
- **Buspirone** has limited evidence of efficacy in GAD compared to SNRIs and is not typically used for **augmentation** in UK clinical practice.
- The guidelines prioritize switching to a different class of primary antidepressant rather than adding low-efficacy adjuncts at this stage.
*Add diazepam 5mg three times daily for ongoing use*
- **Benzodiazepines** such as diazepam should not be used for long-term management of GAD due to high risks of **tolerance** and **physical dependence**.
- They are only indicated for **short-term** (2–4 weeks) crisis management or to cover the initial side effects of starting an antidepressant.
*Augment with quetiapine*
- **Quetiapine** augmentation is considered an advanced strategy for **treatment-resistant GAD**, typically initiated by specialists after multiple first-line agents have failed.
- Due to its **metabolic side effects** and sedative properties, it is not the appropriate next step before trying a licensed **SNRI**.
Question 42: A 63-year-old woman with a 10-week history of severe depression presents with profound psychomotor retardation, complete loss of appetite with 8kg weight loss, and delusional beliefs that her internal organs are rotting. She refuses to eat or drink. Physical examination reveals marked dehydration. Blood tests show acute kidney injury. She has previously failed trials of sertraline and mirtazapine. What is the most appropriate next management step?
A. Commence venlafaxine and arrange urgent psychiatric outpatient review
B. Admit for urgent electroconvulsive therapy (Correct Answer)
C. Start combination therapy with fluoxetine and olanzapine
D. Arrange for augmentation with lithium and continue current antidepressant
E. Initiate high-dose mirtazapine 45mg and monitor as outpatient
Explanation: ***Admit for urgent electroconvulsive therapy***- **Electroconvulsive therapy (ECT)** is the treatment of choice in life-threatening psychiatric emergencies where rapid response is required, such as **refusal of food/fluids** and **acute kidney injury**.- This patient exhibits **Cotard’s syndrome** (delusions of rotting organs) and severe psychomotor retardation, both of which are highly responsive to ECT as a first-line intervention.*Commence venlafaxine and arrange urgent psychiatric outpatient review*- **Venlafaxine** (an SNRI) is insufficient in this scenario as oral medications take weeks to reach therapeutic effect, which the patient cannot afford given her medical stability.- Outpatient review is inappropriate because the patient has developed **acute renal failure** and requires inpatient medical and psychiatric monitoring.*Start combination therapy with fluoxetine and olanzapine*- While combining an **antidepressant and antipsychotic** is a standard treatment for psychotic depression, it is not rapid enough to address the immediate risk of **dehydration and starvation**.- The severity of the clinical presentation (physical deterioration) prioritizes ECT, which has a faster **onset of action** than pharmacological combinations.*Arrange for augmentation with lithium and continue current antidepressant*- **Lithium augmentation** is a strategy for treatment-resistant depression but is contraindicated here due to the presence of **acute kidney injury** (AKI).- Lithium is primarily **renally excreted**, and its use in a dehydrated patient with AKI would lead to a high risk of **lithium toxicity**.*Initiate high-dose mirtazapine 45mg and monitor as outpatient*- Increasing the dose of **mirtazapine** would not provide the urgent intervention needed for a patient who has already failed two antidepressant trials and is physically unstable.- **Outpatient monitoring** is unsafe for a patient with delusional psychosis and severe physical complications requiring **intravenous rehydration**.
Question 43: A 56-year-old woman with recurrent depressive disorder has been stable on fluoxetine 40mg daily for 18 months following her third depressive episode. She wishes to discontinue her antidepressant as she feels fully recovered and dislikes taking medication. Her previous episodes occurred 7 years ago and 4 years ago, both requiring 6-8 months of treatment. She has no current depressive symptoms and good social support. According to current NICE guidance, what is the most appropriate advice regarding discontinuation?
A. Advise continuing fluoxetine for at least another 6 months before considering discontinuation
B. Support discontinuation but recommend rapid taper over 1-2 weeks given her stable condition
C. Advise continuing treatment indefinitely given her three episodes of depression
D. Support gradual discontinuation but advise this should be done over at least 4 weeks (Correct Answer)
E. Advise switching to a lower dose of fluoxetine 20mg for 6 months before stopping completely
Explanation: ***Support gradual discontinuation but advise this should be done over at least 4 weeks*** - NICE guidelines state that antidepressants should be withdrawn gradually over a period of at least **4 weeks** to minimize the risk of **discontinuation syndrome**.- Although this patient has had three episodes, she has completed **18 months** of maintenance therapy, making it reasonable to support her choice to stop, provided it is done safely.*Advise continuing fluoxetine for at least another 6 months before considering discontinuation* - Guidelines suggest considering maintenance for **2 years** after a third episode, but this is a **shared decision** and the patient has a strong preference to stop now after 18 months of stability.- There is no clinical mandate to wait specifically 6 more months if the patient is fully recovered and is currently **euthymic**.*Support discontinuation but recommend rapid taper over 1-2 weeks given her stable condition* - A **rapid taper** (1-2 weeks) increases the risk of **relapse** and physical withdrawal symptoms, regardless of clinical stability.- **Gradual reduction** is essential for all antidepressants, even for those with long half-lives like **fluoxetine**.*Advise continuing treatment indefinitely given her three episodes of depression* - While some guidelines mention maintenance for **at least 2 years** for recurrent depression, "indefinite" treatment is not a mandatory rule and must respect **patient autonomy**.- Given the long intervals (approx. 3 years) between her previous episodes, an attempt at supervised **discontinuation** is clinically acceptable.*Advise switching to a lower dose of fluoxetine 20mg for 6 months before stopping completely* - Simply switching to a lower dose for 6 months does not directly address the patient's immediate desire to **discontinue** the medication.- The recommended protocol is a **progressive reduction** in dose rather than a single step-down for a prolonged fixed duration.
Question 44: A 27-year-old man presents with panic disorder. He experiences unexpected panic attacks 4-5 times per week, characterized by palpitations, sweating, trembling, shortness of breath, and fear of dying. He has developed significant avoidance of situations where escape might be difficult. His GP has explained the diagnosis and offered treatment options. The patient is willing to try either medication or psychological therapy but wants to know which has the best evidence for long-term outcome. What does the evidence suggest about the comparative long-term effectiveness of CBT versus SSRIs for panic disorder?
A. SSRIs have superior long-term outcomes because CBT effects decline rapidly after treatment ends
B. CBT and SSRIs have equivalent long-term outcomes when treatment is maintained
C. CBT has superior long-term outcomes with better maintenance of gains after treatment discontinuation (Correct Answer)
D. SSRIs are superior in the acute phase but CBT becomes more effective after 12 months
E. Combined CBT and SSRI treatment is necessary for sustained long-term benefit
Explanation: ***CBT has superior long-term outcomes with better maintenance of gains after treatment discontinuation***
- Evidence suggests that **Cognitive Behavioural Therapy (CBT)** provides patients with durable skills, such as **exposure techniques** and **cognitive restructuring**, which continue to prevent relapse after the therapist is no longer present.
- While medications are effective, **CBT** demonstrates more robust **maintenance of gains** at 6 to 24-month follow-up assessments compared to pharmacological interventions alone.
*SSRIs have superior long-term outcomes because CBT effects decline rapidly after treatment ends*
- This statement is incorrect as **CBT** is specifically noted for its **enduring effects** and low relapse rates long after the active treatment phase concludes.
- **SSRIs** generally carry a higher risk of **relapse** once the medication is tapered or discontinued compared to psychological therapy.
*CBT and SSRIs have equivalent long-term outcomes when treatment is maintained*
- While outcomes may appear similar during active treatment, **CBT** is generally considered more **cost-effective** and durable in the long term because it does not require indefinite use to maintain benefits.
- Clinical evidence indicates that **treatment gains** from CBT are more likely to persist even after the intervention has technically finished.
*SSRIs are superior in the acute phase but CBT becomes more effective after 12 months*
- Both treatments show similar **efficacy rates** in the acute phase, although **SSRIs** may have a slightly faster **onset of action** for symptom relief.
- It is not that SSRIs are "superior" initially; rather, both are first-line, but the **sustainability** of CBT is what distinguishes it over a 12-month period.
*Combined CBT and SSRI treatment is necessary for sustained long-term benefit*
- Although **combination therapy** can be highly effective in the acute phase, it is not **necessary** for long-term recovery; many patients achieve sustained remission with **monotherapy** (specifically CBT).
- Some evidence even suggests that certain medications (like benzodiazepines) might interfere with the **habituation process** required for CBT to be fully effective.
Question 45: A 48-year-old woman with treatment-resistant depression has failed adequate trials of sertraline, mirtazapine, and venlafaxine. She is currently taking venlafaxine 225mg daily. Her psychiatrist considers augmentation with lithium carbonate. Before initiating lithium, which combination of investigations must be performed as a baseline assessment?
A. Thyroid function tests, renal function, ECG, full blood count
B. Thyroid function tests, renal function, calcium levels, ECG (Correct Answer)
C. Renal function, liver function tests, thyroid function tests, ECG
D. Thyroid function tests, renal function, ECG, bone profile
E. Thyroid function tests, renal function, calcium levels, prolactin level
Explanation: ***Thyroid function tests, renal function, calcium levels, ECG***
- **Lithium** is primarily excreted by the kidneys and can cause **hypothyroidism** and **hyperparathyroidism**, necessitating baseline **renal function (eGFR)**, **TSH**, and **calcium levels**.
- An **ECG** is required per guidelines (NICE/Maudsley) to rule out pre-existing conduction abnormalities, especially in patients with cardiac risk factors or those over 40-50 years old.
*Thyroid function tests, renal function, ECG, full blood count*
- While **thyroid** and **renal** tests are essential, a **Full Blood Count (FBC)** is not a standard requirement for monitoring lithium therapy.
- This option omit **calcium levels**, which are critical due to the risk of lithium-induced **hypercalcaemia**.
*Renal function, liver function tests, thyroid function tests, ECG*
- **Lithium** is not metabolized by the liver, making **Liver Function Tests (LFTs)** unnecessary for its baseline assessment.
- This selection fails to include **calcium level** monitoring, a key safety requirement due to potential **parathyroid** disturbance.
*Thyroid function tests, renal function, ECG, bone profile*
- Although a **bone profile** includes calcium, clinical guidelines specifically emphasize **serum calcium** as the primary electrolyte of concern beyond renal markers.
- The correct option focusing on **calcium levels** is generally preferred over the broader bone profile in professional examinations based on specific adverse effect monitoring (hyperparathyroidism).
*Thyroid function tests, renal function, calcium levels, prolactin level*
- **Prolactin levels** are monitored for antipsychotic medications that block **dopamine** (D2 receptors), not for **lithium**.
- This option also misses the mandatory **ECG** assessment required for patients initiating lithium to ensure baseline cardiac safety.
Question 46: A 33-year-old woman presents with recurrent panic attacks over the past 5 months. She describes sudden episodes of palpitations, sweating, trembling, and feeling like she cannot breathe, accompanied by intense fear of dying. Between attacks, she worries constantly about having another attack and has started avoiding shopping centres and public transport. She has no other psychiatric history. Cardiovascular examination and ECG are normal. She wishes to understand the psychological mechanisms underlying her condition. Which cognitive model best explains the maintenance of her panic disorder?
A. Classical conditioning where panic attacks become associated with specific triggers through repeated pairing
B. Catastrophic misinterpretation of normal bodily sensations leading to a self-perpetuating cycle of anxiety (Correct Answer)
C. Learned helplessness resulting from inability to control or predict panic attacks
D. Operant conditioning where avoidance behaviours are negatively reinforced by anxiety reduction
E. Dysfunctional schemas from early childhood experiences of abandonment or unpredictability
Explanation: ***Catastrophic misinterpretation of normal bodily sensations leading to a self-perpetuating cycle of anxiety***
- This model, developed by **David Clark**, explains that panic attacks arise when physiological signals (e.g., palpitations) are incorrectly perceived as evidence of a disaster like a **heart attack** or **imminent death**.
- This creates a **positive feedback loop** where the resulting anxiety produces more physical symptoms, which further confirms the patient's fears, maintaining the **panic cycle**.
*Classical conditioning where panic attacks become associated with specific triggers through repeated pairing*
- This describes how **neutral stimuli** (like a shopping center) become **conditioned triggers** for anxiety after being paired with a panic event.
- While it explains why specific environments trigger fear, it does not explain the **cognitive appraisal** of internal sensations that drives the attack itself.
*Learned helplessness resulting from inability to control or predict panic attacks*
- This theory suggests that repeated exposure to **uncontrollable stressors** leads to a state of passivity and and is primarily a model for **depression**.
- While patients with panic disorder may feel helpless, this model does not account for the **autonomic arousal** and cognitive distortions seen in panic attacks.
*Operant conditioning where avoidance behaviours are negatively reinforced by anxiety reduction*
- This explains the maintenance of **agoraphobia** and avoidance, where escaping a situation leads to a **reduction in distress**, reinforcing the habit of avoiding.
- While important for understanding **safety behaviors**, it is a behavioral explanation rather than the primary **cognitive model** for the panic mechanism.
*Dysfunctional schemas from early childhood experiences of abandonment or unpredictability*
- These are **long-standing cognitive frameworks** often associated with **personality disorders** or chronic depression rather than acute panic events.
- Panic disorder is better explained by **state-specific misinterpretations** of physical sensations rather than these deep-seated, early developmental schemas.
Question 47: A 61-year-old woman with moderate depression has been taking citalopram 40mg daily for 4 weeks with good tolerability but minimal symptom improvement. Blood tests reveal a sodium level of 128 mmol/L (normal range 135-145 mmol/L). She is clinically euvolaemic with no signs of fluid overload or dehydration. Her thyroid function, glucose, and lipid profiles are normal. She takes no other regular medications. What is the most likely diagnosis?
A. SSRI-induced syndrome of inappropriate antidiuretic hormone secretion (Correct Answer)
B. Adrenal insufficiency
C. Renal salt-wasting syndrome
D. Primary hypothyroidism causing hyponatraemia
E. Psychogenic polydipsia related to depression
Explanation: ***SSRI-induced syndrome of inappropriate antidiuretic hormone secretion***- SSRIs like **citalopram** are a common cause of **SIADH**, particularly in **elderly patients** and often within the first few weeks of treatment.- The patient's **hyponatraemia** (128 mmol/L) with **euvolaemic** status, along with normal thyroid and adrenal function (implied by normal labs and no symptoms), strongly points to SIADH.*Adrenal insufficiency*- **Adrenal insufficiency** usually causes **hypovolaemic hyponatraemia** due to mineralocorticoid deficiency, often accompanied by **hyperkalaemia** and **hypotension**.- The patient is **euvolaemic** and has no other clinical signs like hyperpigmentation or postural hypotension, making this diagnosis less likely.*Renal salt-wasting syndrome*- **Renal salt-wasting syndrome** is characterized by **hypovolaemia** and significant sodium loss in the urine, often associated with intracranial disease.- The patient is described as **euvolaemic** and without signs of dehydration or fluid overload, which rules out this condition.*Primary hypothyroidism causing hyponatraemia*- The patient's **thyroid function tests** are explicitly stated as **normal**, directly contradicting primary hypothyroidism as the cause.- Hyponatraemia due to **hypothyroidism** is typically seen in severe, prolonged cases and is generally accompanied by other clear symptoms of thyroid dysfunction.*Psychogenic polydipsia related to depression*- **Psychogenic polydipsia** involves excessive water intake, leading to **dilutional hyponatraemia** with **low urine osmolality** and typically **polyuria**.- While the patient has depression, the clear association with recent **SSRI initiation** and euvolaemia makes **drug-induced SIADH** a more direct and probable cause.
Question 48: A 44-year-old man with a 4-month history of panic disorder has been taking escitalopram 10mg daily for 6 weeks. He reports that the frequency of his panic attacks has reduced from daily to 2-3 times per week, but he still experiences significant anticipatory anxiety about having attacks. His GP considers increasing the dose. What is the maximum licensed daily dose of escitalopram for panic disorder?
A. 10mg daily
B. 15mg daily
C. 20mg daily (Correct Answer)
D. 30mg daily
E. 40mg daily
Explanation: ***20mg daily***- The maximum licensed daily dose of **escitalopram** for **panic disorder**, as well as for **major depressive disorder** and **social anxiety disorder**, is 20mg daily.- Given the patient's partial response and ongoing anticipatory anxiety after 6 weeks on 10mg, a dose increase up to this maximum is clinically appropriate to achieve full therapeutic effect.*10mg daily*- While 10mg daily is a common starting or maintenance dose for many patients, it is not the **maximum licensed dose** for escitalopram in panic disorder.- The patient's persistent symptoms indicate that 10mg is insufficient to achieve full symptom control, thus warranting a dose escalation.*15mg daily*- Although a 15mg dose might be used during titration for some individuals, it is not recognized as the **maximum licensed daily dose** for escitalopram.- The official prescribing information and clinical guidelines define the upper limit for safety and efficacy at 20mg daily.*30mg daily*- This dose exceeds the **maximum licensed daily dose** of 20mg for escitalopram in panic disorder and other indications.- Doses above 20mg are considered **off-label** and are associated with a higher risk of adverse effects, including **QTc prolongation**, without proven additional clinical benefit.*40mg daily*- This dose is significantly above the **maximum licensed daily dose** for escitalopram.- While 40mg is the traditional maximum for **citalopram** (the racemic mixture from which escitalopram is derived), escitalopram at this dose would carry a substantially elevated risk of **cardiac toxicity** and other severe adverse drug reactions.
Question 49: A 38-year-old woman presents with a 6-month history of persistent, excessive worry about multiple everyday concerns including her children's safety, household finances, and her job performance. She finds the worry difficult to control and it occurs most days. She also reports feeling restless, experiencing muscle tension, having poor concentration, and feeling easily fatigued. She has no significant physical health problems. Her GAD-7 score is 16. She declined psychological therapy. What is the most appropriate first-line pharmacological treatment?
A. Pregabalin 150mg twice daily
B. Diazepam 5mg three times daily for 2 weeks then review
C. Sertraline starting at 50mg daily (Correct Answer)
D. Mirtazapine 15mg at night
E. Propranolol 40mg three times daily
Explanation: ***Sertraline starting at 50mg daily*** - According to **NICE guidelines**, a selective serotonin reuptake inhibitor (**SSRI**) like **Sertraline** is the first-line pharmacological treatment for **Generalized Anxiety Disorder (GAD)**, especially when psychological therapy is declined. - It is preferred due to its favorable **safety profile** and effectiveness in addressing the psychological symptoms of chronic worry and tension. *Pregabalin 150mg twice daily* - **Pregabalin** is considered a **second-line** option for GAD if the patient cannot tolerate or does not respond to SSRIs or SNRIs. - There are also increasing concerns regarding its potential for **dependence and misuse**, making it less suitable as an initial choice. *Diazepam 5mg three times daily for 2 weeks then review* - **Benzodiazepines** are not recommended for long-term management of GAD due to the significant risk of **tolerance and dependence**. - They may be used briefly for **acute crisis management**, but they do not treat the underlying pathology of a 6-month history of anxiety. *Mirtazapine 15mg at night* - While **Mirtazapine** has sedative and anxiolytic properties, it is not recommended as a **first-line** treatment for GAD. - It is usually reserved for cases where patients have **treatment-resistant** depression/anxiety or significant insomnia as a primary symptom. *Propranolol 40mg three times daily* - **Beta-blockers** like Propranolol only manage the **peripheral autonomic symptoms** of anxiety, such as palpitations and tremors. - They are ineffective against the core **psychological symptoms** of GAD, such as persistent worry and rumination.
Question 50: According to the ICD-10 diagnostic criteria for a depressive episode, what is the minimum duration of symptoms required to make this diagnosis?
A. 1 week
B. 2 weeks (Correct Answer)
C. 4 weeks
D. 6 weeks
E. 8 weeks
Explanation: ***2 weeks***
- According to **ICD-10** criteria, the minimum duration for a **depressive episode** is **two weeks**, ensuring the symptoms represent a persistent change from previous functioning.
- This timeframe is consistent with **DSM-5** and is used to distinguish clinically significant depression from transient shifts in mood or **normal grief**.
*1 week*
- This duration is insufficient for a diagnosis of a **depressive episode** under standard classification systems, which require longer persistence of symptoms.
- A **one-week** duration is, however, the minimum required for the diagnosis of a **manic episode** in the DSM-5.
*4 weeks*
- While symptoms may certainly last this long, **four weeks** is double the minimum requirement set by the **ICD-10** for a depressive episode.
- This timeframe does not align with the standard diagnostic threshold for **acute mood disorders**, though it may be relevant for evaluating treatment response.
*6 weeks*
- This period is much longer than the required diagnostic window and is generally associated with the timing of a **clinical trial** review or the **peak effect** of antidepressants.
- Relying on a **six-week** threshold would delay diagnosis and treatment for patients suffering from severe depressive symptoms.
*8 weeks*
- An **eight-week** requirement is not a standard for a depressive episode; symptoms that persist for **two years** or more would instead point toward **dysthymia** (persistent depressive disorder).
- Using an eight-week minimum would lead to significant **under-diagnosis** and failure to provide timely intervention for those in acute distress.
